Advances in DNA damage response inhibitors in colorectal cancer therapy

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Genomic instability from DNA damage is a cancer hallmark.
• Conventional cancer therapies like radiotherapy and chemotherapy damage DNA but affect normal tissues.
• Advanced colorectal cancer (CRC) patients often lack effective treatments despite molecular and immunotherapy advancements.

Approach:

• This review focuses on DNA damage response (DDR) inhibitors as a novel therapeutic strategy for CRC.
• It elucidates the fundamental principles of DDR inhibitors.
• The review provides an overview of the current clinical application of DDR inhibitors in CRC.

Key Points:

• DDR inhibitors represent a targeted therapy approach for CRC.
• Understanding DDR mechanisms is crucial for developing effective cancer treatments.
• Current integration of DDR inhibitors into clinical practice for CRC is still under investigation.

Conclusions:

• DDR inhibitors offer a potential new treatment option for colorectal cancer patients.
• Further research is needed to overcome limitations and optimize the clinical application of DDR inhibitors.
• This review discusses advancements and challenges in the field of DDR inhibitors for CRC.